U.S. markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    60,977.28
    -416.00 (-0.68%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Lawsuits Filed Against NXTC, FLDM and TCMD - Jakubowitz Law Pursues Shareholders Claims

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / October 19, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Nextcure, Inc. (NASDAQ:NXTC)

CONTACT JAKUBOWITZ ABOUT NXTC:
https://claimyourloss.com/securities/nextcure-inc-loss-submission-form/?id=10284&from=1

The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.

Lead Plaintiff Deadline: November 20, 2020

Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.

Fluidigm Corporation (NASDAQ:FLDM)

CONTACT JAKUBOWITZ ABOUT FLDM:
https://claimyourloss.com/securities/fluidigm-corporation-loss-submission-form/?id=10284&from=1

Class Period: February 7, 2019 - November 5, 2019

Lead Plaintiff Deadline : November 20, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm's revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Tactile Systems Technology, Inc. (NASDAQ:TCMD)

CONTACT JAKUBOWITZ ABOUT TCMD:
https://claimyourloss.com/securities/tactile-systems-technology-inc-loss-submission-form/?id=10284&from=1

Class Period: May 7, 2018 - June 8, 2020

Lead Plaintiff Deadline : November 30, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile's pneumatic compression devices was materially smaller; (2) to induce sales growth and share gains, Tactile and/or its employees were engaged in illicit and illegal sales and marketing activities in violation of applicable federal and state rules and public payer regulations; (3) the foregoing illicit and illegal sales and marketing activities increased the risk of a Medicare audit of Tactile's claims and criminal and civil liability; (4) Tactile's revenues were in part the product of unlawful conduct and thus unsustainable; and that as a result of the foregoing, (5) Defendants' public statements, including Tactile's year-over-year revenue growth, the purported growth drivers, and the effectiveness of Tactile's internal controls over financial reporting were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/611120/Lawsuits-Filed-Against-NXTC-FLDM-and-TCMD--Jakubowitz-Law-Pursues-Shareholders-Claims